Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Envision Healthcare Corporation of Class Action Lawsuit and Upcoming Deadline – EVHC

NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE: EVHC) and certain of its officers. The class action, filed in United States District Court, Middle District of Tennessee, and docketed under 17-cv-01112, is on behalf of a class consisting of investors who purchased or otherwise acquired Envision securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Envision securities between March 2, 2015 and July 21, 2017, both dates inclusive, you have until October 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Envision Healthcare Corporation provides health care services. The Hospital offers surgery, pharmacy, medical imaging, emergency care, and other related health care services. Envision Healthcare serves patients in the United States. At all relevant times, EmCare Holdings, Inc. (“EmCare”) has been one of the Company’s primary operating subsidiaries.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) EmCare routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.

On July 24, 2017, The New York Times reported that hospitals associated with Envision’s subsidiary EmCare were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and subsequently billed at higher rates.

On this news, Envision’s share price fell $2.33, or 3.72%, to close at $60.28 on July 24, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


Go to Source

Sequans Communications SA ADR : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sequans Communications S.A. of Class Action Lawsuit and Upcoming Deadline – SQNS

NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Sequans Communications S.A. (“Sequans” or the “Company”) (NYSE: SQNS) and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and docketed under 17-cv-04707, is on behalf of a class consisting of investors who purchased or otherwise acquired Sequans’ American Depositary Receipts (“ADRs”) securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Sequans ADRs securities between April 29, 2016, and July 31, 2017, both dates inclusive, you have until October 9, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Sequans Communications SA is a fabless designer, developer, and supplier of 4G semiconductor solutions for wireless broadband applications. The Company’s solutions incorporate baseband processor and radio frequency, or RF, transceiver integrated circuits, or ICs, along with its proprietary signal processing techniques, algorithms and software stacks.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was improperly recognizing revenue; and (ii) as a result of the foregoing, Sequans’ public statements were materially false and misleading at all relevant times.

On August 1, 2017, the Company issued a press release entitled, “Sequans Communications Announces Second Quarter 2017 Financial Results,” announcing the financial results for the quarter ended June 30, 2017. Sequans reported revenue of $13.2 million, citing “a reduction of $740,000 related to a product return from an early 2016 tablet-related sale.”

On this news, Sequans’ ADR price fell $0.67, or 18.21%, to close at $3.01 on August 1, 2017, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


Go to Source

Applied Optoelectronics Inc : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Optoelectronics, Inc. of Class Action Lawsuit and Upcoming Deadline – AAOI

NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Applied Optoelectronics, Inc. (“Optoelectronics” or the “Company”) (NASDAQ: AAOI) and certain of its officers. The class action, filed in United States District Court, Southern District of Texas, Houston Division, and docketed under 17-cv-02512, is on behalf of a class consisting of investors who purchased or otherwise acquired Optoelectronics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Optoelectronics securities between July 13, 2017, and August 3, 2017, both dates inclusive, you have until October 4, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Applied Optoelectronics, Inc. develops and manufactures advanced optical products which are the building blocks for broadband and fiber access networks primarily for Internet data center, cable television (CATV), and fiber-to-the-home (FTTH) networking end-market.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a major customer was reducing its purchases of the Company’s 40G receivers; (ii) the loss of this major customer’s business would have a severe negative impact on the Company’s financial performance; and (iii) as a result of the foregoing, Optoelectronics’ public statements were materially false and misleading at all relevant times.

On August 3, 2017, post-market the Company issued a press release entitled “Applied Optoelectronics Reports Second Quarter 2017 Results,” announcing the final financial results for the second quarter of 2017 ending June 30, 2017. Optoelectronics advised investors, in relevant part, that “as we look into the third quarter, we see softer than expected demand for our 40G solutions with one of our large customers that will offset the sequential growth and increased demand we expect in 100G.”

On this news, shares of the Company fell by $33.39 per share, or more than 34%, from its previous closing price to close at $64.60 per share on August 4, 2017, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP


Go to Source

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zillow Group, Inc. of Class Action Lawsuit and Upcoming Deadline – Z

NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ: Z) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, Seattle, is on behalf of a class consisting of investors who purchased or otherwise acquired Zillow securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Zillow securities between February 12, 2016, and August 8, 2017, both dates inclusive, you have until October 23, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Zillow Group, Inc. provides e-commerce services. The Company provides information about homes, real estate listings, and mortgages through their website and mobile applications. Zillow serves homeowners, buyers, sellers, renters, and real estate professionals throughout the United States.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s co-marketing program did not comply with the Real Estate Settlement Procedures Act; and (ii) as a result of the foregoing, Zillow’ public statements were materially false and misleading at all relevant times.

On August 8, 2017, the Company filed a quarterly report on Form 10-Q with the Securities and Exchange Commission, announcing the Company’s financial and operating results for the quarter ended June 30, 2017.

The quarterly report stated that, in April 2017, Zillow received a Civil Investigative Demand from the CFPB. On August 8, 2017, Zillow advised investors that the CFPB has concluded its investigation and “has invited us to discuss a possible settlement and indicated that it intends to pursue further action if those discussions do not result in a settlement.”

Following this news, Zillow’s share price fell $7.43, or 15.5%, over the following two trading days to close at $40.50 on August 10, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP


Go to Source

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Health Insurance Innovations, Inc. of Class Action Lawsuit and Upcoming Deadline – HIIQ

NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Health Insurance Innovations, Inc. (“Health Insurance Innovations” or the “Company”) (NASDAQ: HIIQ) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-06962, is on behalf of a class consisting of investors who purchased or otherwise acquired Health Insurance Innovations securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Health Insurance Innovations securities between August 2, 2017, and September 11, 2017, both dates inclusive, you have until November 10, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Health Insurance Innovations operates as a developer, distributor, and administrator of cloud-based individual health and family insurance plans, and supplemental products in the United States. The Company offers, inter alia, short-term medical plans, hospital indemnity plans, and supplemental insurance products. It designs and structures individual health and family insurance plans, and supplemental products on behalf of insurance carriers and discount benefit providers and market them to individuals through a network of distributors.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Health Insurance Innovations’ application for a key insurance license in its home state of Florida was rejected due to the state’s Office of Insurance Regulation’s (“OIR”) discovery of undisclosed legal actions against Health Insurance Innovations insiders; (ii) Health Insurance Innovations warned the OIR of the anticipated “domino effect” that the rejection was likely to cause, by which the Company would subsequently lose licenses in additional states; and (iii) as a result of the foregoing, Health Insurance Innovations’ public statements were materially false and misleading at all relevant times.

On September 11, 2017, the website SeekingAlpha.com published an article reporting on the OIR?s June 2017 rejection of Health Insurance Innovations’ application for a “key insurance license in [its] home state of Florida as [the OIR] uncovers undisclosed legal actions against HIIQ insiders” and that “HIIQ privately warns of disastrous ‘domino effect’ spreading to other states, causing additional loss of licenses. HIIQ makes no disclosure to investors.”

On this news, Health Insurance Innovations’ share price fell $6.55, or 21.91%, to close at $23.35 on September 11, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Health Insurance Innovations, Inc. of Class Action Lawsuit and Upcoming Deadline – HIIQ

Sep 16, 2017 (ACCESSWIRE via COMTEX) — NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Health Insurance Innovations, Inc. (“Health Insurance Innovations” or the “Company”)

HIIQ, +5.14%

and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-06962, is on behalf of a class consisting of investors who purchased or otherwise acquired Health Insurance Innovations securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Health Insurance Innovations securities between August 2, 2017, and September 11, 2017, both dates inclusive, you have until November 10, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Health Insurance Innovations operates as a developer, distributor, and administrator of cloud-based individual health and family insurance plans, and supplemental products in the United States. The Company offers, inter alia, short-term medical plans, hospital indemnity plans, and supplemental insurance products. It designs and structures individual health and family insurance plans, and supplemental products on behalf of insurance carriers and discount benefit providers and market them to individuals through a network of distributors.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Health Insurance Innovations’ application for a key insurance license in its home state of Florida was rejected due to the state’s Office of Insurance Regulation’s (“OIR”) discovery of undisclosed legal actions against Health Insurance Innovations insiders; (ii) Health Insurance Innovations warned the OIR of the anticipated “domino effect” that the rejection was likely to cause, by which the Company would subsequently lose licenses in additional states; and (iii) as a result of the foregoing, Health Insurance Innovations’ public statements were materially false and misleading at all relevant times.

On September 11, 2017, the website SeekingAlpha.com published an article reporting on the OIR’s June 2017 rejection of Health Insurance Innovations’ application for a “key insurance license in [its] home state of Florida as [the OIR] uncovers undisclosed legal actions against HIIQ insiders” and that “HIIQ privately warns of disastrous ‘domino effect’ spreading to other states, causing additional loss of licenses. HIIQ makes no disclosure to investors.”

On this news, Health Insurance Innovations’ share price fell $6.55, or 21.91%, to close at $23.35 on September 11, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

http://www.accesswire.com/img.ashx?id=475576

Copyright 2017 ACCESSWIRE

Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zillow Group, Inc. of Class Action Lawsuit and Upcoming Deadline – Z

Sep 16, 2017 (ACCESSWIRE via COMTEX) — NEW YORK, NY / ACCESSWIRE / September 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (“Zillow” or the “Company”)

Z, +0.85%

and certain of its officers. The class action, filed in United States District Court, Western District of Washington, Seattle, is on behalf of a class consisting of investors who purchased or otherwise acquired Zillow securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Zillow securities between February 12, 2016, and August 8, 2017, both dates inclusive, you have until October 23, 2017, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Zillow Group, Inc. provides e-commerce services. The Company provides information about homes, real estate listings, and mortgages through their website and mobile applications. Zillow serves homeowners, buyers, sellers, renters, and real estate professionals throughout the United States.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s co-marketing program did not comply with the Real Estate Settlement Procedures Act; and (ii) as a result of the foregoing, Zillow’ public statements were materially false and misleading at all relevant times.

On August 8, 2017, the Company filed a quarterly report on Form 10-Q with the Securities and Exchange Commission, announcing the Company’s financial and operating results for the quarter ended June 30, 2017.

The quarterly report stated that, in April 2017, Zillow received a Civil Investigative Demand from the CFPB. On August 8, 2017, Zillow advised investors that the CFPB has concluded its investigation and “has invited us to discuss a possible settlement and indicated that it intends to pursue further action if those discussions do not result in a settlement.”

Following this news, Zillow’s share price fell $7.43, or 15.5%, over the following two trading days to close at $40.50 on August 10, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

http://www.accesswire.com/img.ashx?id=475573

Copyright 2017 ACCESSWIRE

Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Top…

NEW YORK, Sept. 16, 2017 /PRNewswire/ — Pomerantz LLP
announces that a class action lawsuit has been filed against Top Ships Inc. (“Top Ships” or the “Company”) (NASDAQ: TOPS)
and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and docketed under 17-cv-05016, is on behalf of a class consisting of investors who purchased or
otherwise acquired Top Ships securities, seeking to recover compensable damages caused by defendants’ violations of the
Securities Exchange Act of 1934.

If you are a shareholder who purchased Top Ships securities between January 17, 2017, and
August 22, 2017, both dates inclusive, you have until October 23,
2017
, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at
www.pomerantzlaw.com.   To discuss this action,
contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are
encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here to join
this class action]

Top Ships is an international provider of oil, petroleum products and chemicals transportation services.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding
the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements
and/or failed to disclose that the Company’s CEO, Evangelos J. Pistiolis (“Pistiolis”), through
his control of Top Ships, caused Top Ships to engage in a series of manipulative share issuance/sales transactions with Kalani
Investments Limited and certain of its related entities (“Kalani”) through which Top Ships would sell its common shares and
securities convertible into common shares to Kalani at a significant discount to market price and file registration statements so
that Kalani could resell these shares into the market. When Kalani’s sales of Top Ships stock caused the price of Top Ships stock
to decline, the Company would reverse split the stock, causing a certain number of outstanding shares to be merged into a single
share, and thereby raise the price of Top Ships stock. Then, Top Ships would again sell securities to Kalani and the same pattern
of transactions would ensue. At the same time that Top Ships was engaging in these transactions, defendants failed to disclose
the true purpose of the transactions and related stock issuances and reverses – to finance related-party transactions and
acquisitions that primarily benefited Pistiolis and his related companies, and otherwise funnel money to Company
insiders.   

By August 2017, Top Ships, through Kalani, had issued and sold into the market tens of millions
of shares of its common stock, vastly diluting the Company’s existing shareholders. While Top Ships has allegedly used the
proceeds from these offerings to further enrich Pistiolis and his affiliates through various related-party transactions, the
value of Top Ships common stock has dropped over 99%.

The Pomerantz Firm, with offices in New York, Chicago,
Los Angeles, and Paris, is acknowledged as one of the premier
firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham
L. Pomerantz
, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class
actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights
of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Go to Source

National Association of Minority & Women Owned Law Firms Annual Meeting

Exponent is a proud sponsor of the 2017 National Association of Minority & Women Owned Law Firms (NAMWOLF) Annual Meeting. The event will be held in New York, New York on September 17 through September 20, 2017

The NAMWOLF Annual Meeting & Law Firm Expo is a three-day conference providing unique opportunities to connect corporate counsel from Fortune 1000 companies and minority and women owned law firms. The conference features NAMWOLF’s signature event, the Law Firm Expo, which provides an opportunity for In-House Counsel to meet with the Nation’s top minority and women owned law firms. Guests will be given the opportunity to attend CLE sessions and many networking events.

For more information, please visit the event website.

Exponent Inc. published this content on 17 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 September 2017 00:03:07 UTC.


Go to Source

Exponent : National Association of Minority & Women Owned Law Firms Annual Meeting

Exponent is a proud sponsor of the 2017 National Association of Minority & Women Owned Law Firms (NAMWOLF) Annual Meeting. The event will be held in New York, New York on September 17 through September 20, 2017

The NAMWOLF Annual Meeting & Law Firm Expo is a three-day conference providing unique opportunities to connect corporate counsel from Fortune 1000 companies and minority and women owned law firms. The conference features NAMWOLF’s signature event, the Law Firm Expo, which provides an opportunity for In-House Counsel to meet with the Nation’s top minority and women owned law firms. Guests will be given the opportunity to attend CLE sessions and many networking events.

For more information, please visit the event website.

Exponent Inc. published this content on 17 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 September 2017 00:03:07 UTC.


Go to Source